Injections of TREM2 agonistic antibodies, which boost the numbers of DAM in the brain, have succeeded in inhibiting amyloid pathology in mice, and related phase 2 clinical trials are currently being conducted to develop new drugs for AD (S. T. Wang et al., 2020). Here, TREM2 is linked to amyloidosis.